Copyright
©The Author(s) 2023.
World J Gastrointest Oncol. Nov 15, 2023; 15(11): 1900-1912
Published online Nov 15, 2023. doi: 10.4251/wjgo.v15.i11.1900
Published online Nov 15, 2023. doi: 10.4251/wjgo.v15.i11.1900
Table 1 Baseline patient characteristics, n (%)
Variable | Category | No AEs or AEs grade < 2 | AEs grade ≥ 2 | OR | 95%CI | P value |
n = 361 | 274 (76)1 | 87 (24) | ||||
Age (Median) | 65 | 64 | 0.99 | (0.97, 1.01) | 0.450 | |
Sex | Male | 222 (61) | 65 (18) | 1.00 | ||
Female | 52 (14) | 22 (7) | 1.44 | (0.82, 2.56) | 0.206 | |
AFP (Median) | 115 | 29 | 1.00 | (1, 1) | 0.850 | |
Known cirrhosis | Yes | 201 (56) | 62 (17) | 0.90 | (0.53, 1.54) | 0.702 |
No | 73 (20) | 25 (7) | 1.00 | |||
Known PVT | Yes | 61 (17) | 18 (5) | 0.60 | (0.33, 1.1) | 0.100 |
No | 124 (34) | 61 (17) | 1.00 | |||
NLR | NLR ≤ 5 | 122 (34) | 62 (17) | 1.00 | ||
NLR > 5 | 54 (15) | 16 (5) | 0.58 | (0.31, 1.1) | 0.096 | |
Unknown | 98 (27) | 9 (2) | ||||
PLR | PLR ≤ 300 | 145 (40) | 72 (20) | 1.00 | ||
PLR > 300 | 31 (9) | 6 (2) | 0.39 | (0.16, 0.98) | 0.044 | |
Unknown | 98 (27) | 9 (2) | ||||
Child pugh class | A | 202 (56) | 74 (20) | 1.00 | ||
B | 61 (17) | 13 (4) | 0.58 | (0.3, 1.12) | 0.105 | |
C | 7 (2) | 0 (0) | 0.00 | (0, Inf) | 0.986 | |
Unknown | 4 (1) | 0 (0) | ||||
HCV | Yes | 112 (31) | 41 (11) | 1.29 | (0.79, 2.09) | 0.305 |
No | 162 (45) | 46 (13) | 1.00 | |||
HBV | Yes | 59 (16) | 18 (5) | 0.95 | (0.53, 1.72) | 0.867 |
No | 215 (60) | 69 (19) | 1.00 | |||
EtOH | Yes | 48 (13) | 17 (5) | 1.14 | (0.62, 2.11) | 0.669 |
No | 226 (63) | 70 (19) | 1.00 | |||
NASH | Yes | 37 (10) | 8 (2) | 0.65 | (0.29, 1.45) | 0.292 |
No | 237 (66) | 79 (22) | 1.00 | |||
BCLCs | A | 9 (2) | 1 (1) | 1.00 | ||
B | 66 (18) | 25 (7) | 3.41 | (0.41, 28.31) | 0.256 | |
C | 194 (53) | 61 (17) | 2.83 | (0.35, 22.79) | 0.328 | |
D | 4 (1) | 0 (0) | 0.00 | (0, Inf) | 0.985 | |
Unknown | 1 (1) | 0 (0) | ||||
Extra Hepatic Disease | Yes | 100 (28) | 36 (10) | 0.73 | (0.43, 1.23) | 0.239 |
No | 87 (24) | 43 (12) | 1.00 | |||
Unknown | 87 (24) | 8 (2) | ||||
ECOG | 0 | 168 (47) | 77 (21) | 1.00 | ||
1 | 18 (5) | 2 (1) | 0.24 | (0.05, 1.07) | 0.062 | |
Unknown | 88 (24) | 8 (2) | ||||
Steroid use | Yes | 57 (16) | 37 (10) | 2.74 | (1.61, 4.64) | 0.0002 |
No | 190 (53) | 45 (12) | ||||
Unknown | 27 (7) | 5 (2) | ||||
Antibiotic use | Yes | 42 (12) | 14 (4) | 1.01 | (0.52, 1.98) | 0.95 |
No | 205 (56) | 67 (19) | ||||
Unknown | 27 (7) | 6 (2) | ||||
Treatment | PD-1 | 244 (68) | 61 (17) | |||
PD-1/CLTA-4 | 16 (4) | 12 (3) | 3.00 | (1.35, 6.67) | 0.007 | |
PD-1/TKI | 12 (3) | 12 (3) | 4.00 | (1.71, 9.34) | 0.001 | |
PD-1/other | 1 (0) | 1 (0) | 4.00 | (0.25, 64.86) | 0.329 | |
CTLA-4 | 1 (0) | 1 (0) | 4.00 | (0.25, 64.86) | 0.32 |
Table 2 Immune-related adverse events incidence by groups1, n (%)
IrAE by organ system n = 167 | Grade < 2 | Grade ≥ 2 |
Dermatological | 43 (26) | 15 (9) |
Colitis | 19 (11) | 10 (6) |
Hepatitis | 40 (24) | 29 (17) |
Endocrine | 18 (11) | 11 (7) |
Polyarthritis | 3 (1) | 1 (0) |
Pneumonitis | 10 (6) | 9 (5) |
Constitutional | 52 (31) | 15 (9) |
Other | 15 (9) | 22 (13) |
Table 3 Univariable and multivariable models to predict grade 2 or higher adverse events
Odds ratio | 95%CI | P value | |
Univariable model: | |||
PLR (> 300) | 0.40 | (0.16, 0.98) | 0.044 |
NLR (> 5) | 0.58 | (0.31, 1.10) | 0.097 |
Steroid use | 2.74 | (1.62, 4.64) | < 0.001 |
Antibiotics use | 1.02 | (0.52, 1.98) | 0.954 |
Treatment | |||
PD-1 CLTA-4 | 3 | (1.35, 6.67) | 0.007 |
PD-1 TKI | 4 | (1.71, 9.34) | 0.001 |
Other1 | 4 | (0.55, 28.97) | 0.170 |
Multivariable model: | |||
PLR (> 300) | 0.26 | (0.09, 0.74) | 0.011 |
Steroid use | 4.43 | (2.21, 8.88) | < 0.001 |
Treatment | |||
PD-1/CLTA-4 | 2.57 | (1.06, 6.24) | 0.037 |
PD-1/TKI | 3.39 | (1.34, 8.56) | 0.01 |
Other1 | 3.50 | (0.21, 57.86) | 0.381 |
- Citation: Dharmapuri S, Özbek U, Jethra H, Jun T, Marron TU, Saeed A, Huang YH, Muzaffar M, Pinter M, Balcar L, Fulgenzi C, Amara S, Weinmann A, Personeni N, Scheiner B, Pressiani T, Navaid M, Bengsch B, Paul S, Khan U, Bettinger D, Nishida N, Mohamed YI, Vogel A, Gampa A, Korolewicz J, Cammarota A, Kaseb A, Galle PR, Pillai A, Wang YH, Cortellini A, Kudo M, D’Alessio A, Rimassa L, Pinato DJ, Ang C. Baseline neutrophil-lymphocyte ratio and platelet-lymphocyte ratio appear predictive of immune treatment related toxicity in hepatocellular carcinoma. World J Gastrointest Oncol 2023; 15(11): 1900-1912
- URL: https://www.wjgnet.com/1948-5204/full/v15/i11/1900.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v15.i11.1900